TIDMMDST 
 
RNS Number : 3744C 
Medicsight Plc 
12 November 2009 
 

+------------------------------------+------------------------------------+ 
| Press Release                      |                   12 November 2009 | 
+------------------------------------+------------------------------------+ 
 
 
Medicsight PLC 
 
 
("Medicsight" or "the Company") 
 
 
Third Quarter Results 
 
 
Medicsight PLC (AIM: MDST), industry leader in the development of Computer-Aided 
Detection (CAD) and image analysis software to assist in the early detection and 
diagnosis of disease, is pleased to announce its third quarter results for the 
nine months ended 30 September 2009. 
 
 
Summary Financial Data 
+------------------------------------+---------------------------------------------------------------+ 
|                                *   | The Group's cash and equivalents balance at 30 September 2009 | 
|                                    | was GBP12,335,000 (30 September 2008: GBP20,613,000)          | 
+------------------------------------+---------------------------------------------------------------+ 
|                                *   | The Group's total assets position at 30 September 2009 was    | 
|                                    | GBP13,410,000 (30 September 2008: GBP21,986,000)              | 
+------------------------------------+---------------------------------------------------------------+ 
|                                *   | Net revenue from external customers was GBP94,000 (30         | 
|                                    | September 2008: GBP57,000)                                    | 
+------------------------------------+---------------------------------------------------------------+ 
|                                *   | Operating loss before interest and tax of GBP6,626,000 (30    | 
|                                    | September 2008: GBP7,301,000)                                 | 
+------------------------------------+---------------------------------------------------------------+ 
 
 
Medicsight continues to work closely with the US Food and Drug Administration 
authorities ("the FDA") and the Japanese Ministry of Health, Labour and Welfare 
("MHLW") as they conduct their reviews of its product regulatory submissions. 
 
 
Medicsight remains in a healthy cash position with a cash balance of GBP12.3 
million at 30 September 2009. 
 
 
- ENDS - 
 
For further information: 
+-------------------------------------------+----------------------------+ 
| Medicsight plc                            |                            | 
+-------------------------------------------+----------------------------+ 
| Allan Rowley, CEO                         | Tel: +44 (0)207 605 7950   | 
+-------------------------------------------+----------------------------+ 
|                                           | www.medicsight.com         | 
+-------------------------------------------+----------------------------+ 
| Daniel Stewart & Co                       |                            | 
+-------------------------------------------+----------------------------+ 
| Simon Leathers / Oliver Rigby             | Tel: +44 (0) 207 776 6550  | 
+-------------------------------------------+----------------------------+ 
|                                           | www.danielstewart.co.uk    | 
+-------------------------------------------+----------------------------+ 
Media enquiries: 
+-------------------------------------------+----------------------------+ 
| Abchurch                                  | Tel: +44 (0) 207 398 7700  | 
+-------------------------------------------+----------------------------+ 
| Heather Salmond/Stephanie Cuthbert/Simone | Tel: +44 (0) 207 398 7704  | 
| Alves                                     |                            | 
+-------------------------------------------+----------------------------+ 
| heather.salmond@abchurch-group.com        | www.abchurch-group.com     | 
+-------------------------------------------+----------------------------+ 
 
 
Notes to editors 
Medicsight plc is a UK-headquartered, research driven, leading developer of 
computer-aided detection (CAD) and image analysis software for the medical 
imaging market. The CAD software automatically highlights suspicious areas on 
computerised tomography (CT) scans of the colon and lung, helping radiologists 
to identify, measure and analyse potential disease and early indicators of 
disease. Medicsight's CAD software has been validated using one of the world's 
largest and most population diverse databases of verified patient CT scan data. 
Medicsight's ColonCAD(TM) and LungCAD(TM) software products are seamlessly 
integrated with the advanced 3D visualisation workstations of several 
industry-leading imaging equipment partners. 
 
 
About Computer-Aided Detection 
With increasingly sophisticated radiological imaging hardware such as 
Multi-Detector CT scanners, radiologists are facing a growing challenge in the 
amount of detailed patient image data that they must review for each patient 
examination. Some CT scan examinations generate as many as 2000 images per 
patient. Review of this data by the radiologist is not only time-consuming but 
also prone to error due to reader fatigue. CAD software can help the reviewing 
radiologist by analysing the image data and automatically highlighting 
suspicious regions of interest for closer inspection. Without CAD software some 
potential abnormalities or areas of disease may be overlooked. This can be 
critical for diagnosis and the management of patient outcomes as early detection 
of disease greatly increases the probability of successful treatment and a 
positive therapeutic outcome. In addition to supporting individual radiologists 
CAD also has the potential to help standardise CT interpretation across both 
individuals and institutions thereby supporting population based screening 
programmes. 
 
 
About Medicsight's CAD software 
Medicsight's ColonCAD(TM) and LungCAD(TM) software use an advanced CAD algorithm 
to analyse CT scans of the colon and lung and automatically highlight suspicious 
areas that may be indicators of disease. CAD may highlight areas easily 
overlooked by the reviewing radiologist, such as small lesions or regions that 
are hidden from view behind folds in the colon or normal structures and 
surrounding tissue in the lung. 
 
 
Both CAD products seamlessly integrate with the advanced 3D visualisation 
platforms of industry-leading imaging equipment partners. The integrated systems 
provide sophisticated image viewing capabilities, including 3D reconstructed 
image data, with the added advantage of demonstrating automatic CAD findings to 
assist clinical end users in the detection and analysis of disease. This allows 
clinical end users to perform either a 'second read', where CAD findings are 
displayed to the user after completion of an initial review of the CT scan data, 
or a 'concurrent read' where CAD findings are displayed during the user's 
initial review of the original CT scan images. 
 
 
Since inception, Medicsight has developed close and lasting relationships with 
some of the world's foremost clinicians in product related areas. This provides 
the Company with a wealth of clinical expertise and dedicated clinical research 
to support ongoing product development. Medicsight also collaborates with a 
number of leading academic institutions and clinical research programmes 
worldwide to develop the Company's comprehensive database of population diverse 
verified patient CT scan data, thus allowing Medicsight's products to be 
validated to the highest possible standards. 
 
 
 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 QRTFFIFWFSUSEFF
Medicsight (LSE:MDST)
Historical Stock Chart
Von Nov 2024 bis Dez 2024 Click Here for more Medicsight Charts.
Medicsight (LSE:MDST)
Historical Stock Chart
Von Dez 2023 bis Dez 2024 Click Here for more Medicsight Charts.